Tarsus Pharmaceuticals (TARS) to Announce Earnings on Thursday

Tarsus Pharmaceuticals (NASDAQ:TARS) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.21) per share and revenue of $169.1110 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. On average, analysts expect Tarsus Pharmaceuticals to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Performance

TARS stock opened at $58.52 on Thursday. The firm has a 50 day simple moving average of $61.31 and a 200 day simple moving average of $65.51. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $85.25. The stock has a market cap of $2.52 billion, a P/E ratio of -51.33 and a beta of 0.50. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74.

Analyst Ratings Changes

TARS has been the subject of a number of research analyst reports. Guggenheim cut their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Tuesday, July 21st. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $90.50.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Jeffrey S. Farrow sold 14,396 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total value of $877,436.20. Following the completion of the sale, the insider directly owned 56,801 shares of the company’s stock, valued at $3,462,020.95. The trade was a 20.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katherine Goodrich sold 2,954 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the transaction, the director owned 2,233 shares in the company, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,850 shares of company stock valued at $2,452,821 over the last three months. 9.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Truvestments Capital LLC increased its position in Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $202,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $205,000. Cibc World Markets Corp bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $212,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.